Table 1.
Study and clinical characteristics of prostate cancer participants.
| Characteristics | Tumour (n = 122) | Adjacent benign (n = 42) | p-valuea |
|---|---|---|---|
| Study n (%) | |||
| MCCS | 55 (45.1) | 21 (50) | 0.66 |
| RFPCS | 28 (23) | 8 (19) | |
| RPR | 12 (9.8) | 5 (11.9) | |
| EOPCFS | 25 (20.5) | 6 (14.3) | |
| APC | 2 (1.6) | 2 (4.8) | |
| Age at diagnosis, years, n (%) | |||
| < 65 | 56 (45.9) | 15 (35.7) | 0.25 |
| ≥ 65 | 66 (54.1) | 27 (64.3) | |
| Sample type n (%) | |||
| TRUS | 69 (56.6) | 15 (35.7) | 0.02 |
| TURP | 53 (43.4) | 27 (64.3) | |
| Gleason Score n (%) | |||
| 2–6 | 10 (8.2) | ||
| 7 = 3 + 4 | 24 (19.7) | ||
| 7 = 4 + 3 | 25 (20.5) | ||
| 8–10 | 63 (51.6) | ||
| Vital Status n (%) | |||
| Alive | 28 (22.9) | 12 (28.6) | 0.82 |
| Prostate cancer death | 84 (68.9) | 28 (66.6) | |
| Other death | 9 (7.4) | 2 (4.8) | |
| Unknown cause of death | 1 (0.8) | 0 (0.0) | |
aP-values derived from the Chi-square test. A p-value < 0.05 is considered significant.